tbuckley/cabot-search huggingface dataset:
Pericardial Synovial Sarcoma Followed Up With Contrast-Enhanced PET-CT
Authors: Avani S. Jain, Shelley Simon, Indirani Muthukrishnan, Aashish Gambhir, Sushma Patil
Journal: Clinical Nuclear Medicine (2017)

Pericardial synovial sarcoma is an extremely rare tumor, and a challenging diagnosis due to nonspecific diverse presentation requiring a very strong clinical acumen along with an aggressive multimodal approach. Histopathological confirmation remains the gold standard. The optimal management is unclear because of very few cases reported in literature. Herein, we describe the findings on contrast-enhanced FDG PET-CT facilitating the staging, lesion characterization, and timely response assessment to chemotherapy.
Generation of Induced Pluripotent Stem Cell-Derived Erythroblasts from a Patient with X-Linked Sideroblastic Anemia
Authors: Shunsuke Hatta, Tohru Fujiwara, Takako Yamamoto, Mayumi Kamata, Yoshiko Tamai, Yukio Nakamura, Shin Kawamata, Hideo Harigae
Journal: Blood (2016)
Is Social Media a Cesspool of Misinformation? Clearing a Path for Patient-Friendly Safe Spaces Online
Authors: Yael Frish, Dov Greenbaum
Journal: The American Journal of Bioethics (2017)

The 2016 election cycle put a particular focus on the problems associated with sheltered social media bubbles and the resulting naivete of many otherwise smart denizens of the Internet. These probl...
Identification of new prognostic factors in phase I patients treated by immunotherapy
Authors: F. Bigot, E. Castanon Alvarez, A. Hollebecque, A. Carmona, S. Postel-Vinay, E. Angevin, J.-P. Armand, V. Ribrag, S. Aspeslagh, A. Varga, R. Bahleda, A. Gazzah, C. Bonnet, J.-M. Michot, A. Marabelle, J.-C. Soria, C. Massard
Journal: Annals of Oncology (2016)
Safety and efficacy of lanreotide autogel/depot (LAN) every 14 days for patients with pancreatic or midgut neuroendocrine tumours (NETs) progressing on LAN every 28 days: The prospective, international CLARINET FORTE study
Authors: M. Pavel, C. Dromain, C. Massien, A. Houchard
Journal: Annals of Oncology (2016)
PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA)
Authors: J.L. Legoux, K. Le Malicot, R. Faroux, V. Boige, N. Barriere, J. Egreteau, Y. Rinaldi, E. Maillard, M. Baconnier, C. Lecaille, S. Herrmann-Gandara, A. Vimal, Y. Touchefeu, J. Raimbourg, T. Aparicio
Journal: Annals of Oncology (2016)
CD56+ Monomorphic Enteropathy-Type T-Cell Lymphoma Is a Genetically Distinct Entity Characterized by 8q Gains and Lack of 1q and 5q Gains.
Authors: Ronald J. deLeeuw, Andreas Zettl, Magan Trottier, Randy D. Gascoyne, Andreas Chott, Hans K. Mueller-Hermelink, Wan L. Lam
Journal: Blood (2005)
Genetic analysis of gastric cancer with distinctive family history
Authors: M. Terashima, K. Hatakeyama, M. Kusuhara, R. Makuuchi, M. Tokunaga, Y. Tanizawa, E. Bando, T. Kawamura, M. Hikage, S. Kaji, K. Ohshima, S. Ohnami, K. Urakami, K. Yamaguchi
Journal: Annals of Oncology (2016)
Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.
Authors: Rima M. Saliba, Marcos de Lima, Chitra Hosing, Issa F. Khouri, Sergio Giralt, Paolo Anderlini, Shubhra Ghosh, Kerry Mickler, Cindy Ippoliti, Zuraima Caldera, Yvonne Hsu, Joyce Neumann, Richard Champlin, Daniel R. Couriel
Journal: Blood (2005)
NIMG-03. PREDICTING IDH MUTATION STATUS ON ROUTINE TREATMENT-NAÏVE MRI USING RADIOGENOMIC FEATURES FROM PERITUMORAL BRAIN PARENCHYMA
Authors: Niha Beig, Ramon Correa, Prateek Prasanna, Jhimli Mitra, Anant Madabhushi, Ameya Nayate, Pallavi Tiwari
Journal: Neuro-Oncology (2016)

Mutations in isocitrate dehydrogenase (IDH-mut) are considered one of the strongest independent prognostic markers of survival in glioma. Currently, IDH-mut is determined through DNA sequencing of biopsied tissue. In IDH-mut gliomas, vascular endothelial growth factor (VEGF) expression is antagonized which reduces edema due to its dependence on hypoxia-inducible factors (HIFα). Similarly, IDH wild-type (WT, unmutated) gliomas upregulate VEGF, which induces more edema by high vascular permeability. We hypothesized that the tissue-level morphologic heterogeneity caused due to IDH-mut is reflected in the peritumoral brain parenchyma at the imaging (MRI) scale, and can possibly be captured via directional gradients (Gabor) and local intensity statistics (Haralick, Laws) texture operators. A cohort consisting of 78 studies (glioblastomas =32, low-grade gliomas =46) with T1w, T2w, FLAIR protocols was obtained from the TCIA database. 46 cases were IDH-mut and 32 were IDH-WT. Every lesion was delineated into four possible compartments: enhancing, non-enhancing, necrosis, and edema on each of the 3 protocols by an expert. Four first order statistics (mean, standard deviation, skewness, kurtosis) were derived from the various texture operators (eg., Haralick, Law, Gabor) resulting in 540 features for every sequence. Using t-test (p<0.01) and principal component analysis, a reduced set of orthogonal features were identified, to categorize every study as belonging to IDH/ IDH-WT. Gabor (captures directional gradients) and Laws (captures spotty, and wave-like patterns) features from the peritumoral edema region on T2w MRI were the most significant (p<0.01) predictors of IDH mutation, as compared to the other compartments and protocols. PCA based clustering of T2w features from edema region resulted in a sensitivity of 88.2% (PPV = 0.83, NPV = 0.90). Our results suggest that gradient and intensity statistics texture features within edema enable discrimination of IDH1 mutation vs wild type and warrants further validation on an independent dataset.
Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001
Authors: A. Shaw, G.J. Riley, Y.-J. Bang, D.-W. Kim, D.R. Camidge, M. Varella-Garcia, A.J. Lafrate, G. Shapiro, M. Winter, T. Usari, S.C. Wang, K. Wilner, J.W. Clark, S.-H.I. Ou
Journal: Annals of Oncology (2016)
Evidence for a Novel Blood Lineage Commitment Pathway from Lympho-Myeloid Hematopoietic Stem Cells.
Authors: Sten Eirik W. Jacobsen, Robert Mansson, Anne Hultquist, Mikael Sigvardsson, Natalija Buza-Vidas, Lina Thoren, Karina Liuba, Sidinh Luc, Liping Yang
Journal: Blood (2005)
Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with gastrointestinal and colorectal cancers
Authors: R. Navari, K. Jordan, B.L. Rapoport, I. Schnadig, M. Chasen, S. Arora, D. Powers, L. Schwartzberg
Journal: Annals of Oncology (2016)
P13.15 Multi-fraction stereotactic radiosurgery (MF-SRS) versus surgery plus MF-SRS for patients with large radioresistant brain metastases
Authors: G. Minniti
Journal: Neuro-Oncology (2016)

RESULTS:The overall MS was 17 months and 10. 5, 11, 21, 14, 31, 53 and 16, 5 months for patients with respectively 5, 6, 7, 8, 9, 10 and 11 to 21 BM.According histology, the MS was 25, 9 and 18 months for patients with more than 4 BM with respectively breast, melanoma and lung cancer.CONCLUSIONS: The median survival of patients with more than 4 BM was 17 months and not influenced by histology such as breast, melanoma and lung cancer.The number of BM is not a key factor for survival in patients with otherwise good prognostic factors. P13.
Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells
Authors: Ramin Sedaghat Herati, Alexander Muselman, Laura Vella, Bertram Bengsch, Kaela Parkhouse, Daniel Del Alcazar, Jonathan Kotzin, Susan A. Doyle, Pablo Tebas, Scott E. Hensley, Laura F. Su, Kenneth E. Schmader, E. John Wherry
Journal: Science Immunology (2017)

T follicular helper (Tfh) CD4 cells are crucial providers of B cell help during adaptive immune responses. A circulating population of CD4 T cells, termed cTfh, have similarity to lymphoid Tfh, can provide B cell help, and responded to influenza vaccination. However, it is unclear whether human vaccination-induced cTfh respond in an antigen-specific manner and whether they form long-lasting memory. Here, we identified a cTfh population that expressed multiple T cell activation markers and could be readily identified by coexpression of ICOS and CD38. This subset expressed more Bcl-6, c-Maf, and IL-21 than other blood CD4 subsets. Influenza vaccination induced a strong response in the ICOS+CD38+ cTfh at day 7, and this population included hemagglutinin-specific cells by tetramer staining and antigen-stimulated Activation Induced Marker (AIM) expression. Moreover, TCRB sequencing identified a clonal response in ICOS+CD38+ cTfh that correlated strongly with the increased circulating ICOS+CD38+ cTfh frequency and the circulating plasmablast response. In subjects who received successive annual vaccinations, a recurrent oligoclonal response was identified in the ICOS+CD38+ cTfh subset at 7 days after every vaccination. These oligoclonal responses in ICOS+CD38+ cTfh after vaccination persisted in the ICOS-CD38- cTfh repertoire in subsequent years, suggesting clonal maintenance in a memory reservoir in the more-stable ICOS-CD38- cTfh subset. These data highlight the antigen-specificity, lineage relationships and memory properties of human cTfh responses to vaccination, providing new avenues for tracking and monitoring cTfh responses during infection and vaccination in humans.
Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms
Authors: Bianca Tesi, Josef Davidsson, Matthias Voss, Elisa Rahikkala, Tim D. Holmes, Samuel C. C. Chiang, Jonna Komulainen-Ebrahim, Sorina Gorcenco, Alexandra Rundberg Nilsson, Tim Ripperger, Hannaleena Kokkonen, David Bryder, Thoas Fioretos, Jan-Inge Henter, Merja Möttönen, Riitta Niinimäki, Lars Nilsson, Cornelis Jan Pronk, Andreas Puschmann, Hong Qian, Johanna Uusimaa, Jukka Moilanen, Ulf Tedgård, Jörg Cammenga, Yenan T. Bryceson
Journal: Blood (2017)
Mobilization Studies in Complement-Deficient Mice Reveal That AMD3100 Mobilization Depends On Complement Cascade Activation and Suggest Involvement of “Membrane Attack Complex - MAC” in Egress of Hematopoietic Stem/Progenitor Cells.
Authors: Marcin Wysoczynski, HakMo Lee, Rui Liu, Wan Wu, Janina Ratajczak,, Mariusz Z Ratajczak
Journal: Blood (2009)
Research of Gene Expression in Patients with Myelodysplastic Syndromes.
Authors: Bao-An Chen, Bo Zhang, Chong Gao, Guo-Hua Xia, Ze-ye Shao, Jia-Hua Ding, Jian Chen, Jun Wang, Hui-Hui Song, Wen Bao, Yue-Jiao Zhong, Xiao-Ping Pei, Fei Wang, Ning-Na Chen
Journal: Blood (2009)
Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02
Authors: A.J. Rullan Iriarte, S. Martín-Algarra, Ldela Cruz Merino, D. Rodriguez Abreu, E. Espinosa, A. Berrocal, R. López Castro, T. Curiel, P. Luna, A. Lorenzo, J.M. Piulats
Journal: Annals of Oncology (2016)
Naturally occurring immune response against biologically and clinically relevant targets
Authors: J.P. Marquez, S. Carrillo, A. Suplee-Rivera, E. Ramos, P.A. Lucero-Diaz, A. Camacho-Hernandez, J.A. Matute-Briseno, R. Soto-Soto
Journal: Annals of Oncology (2016)
Epidermal Growth Factor-like Domain 7 Promotes Hematopoietic Stem Cell Expansion and Increases Myeloid-Megakaryocytic Lineage Priming through beta3 Integrin
Authors: Chiemi Nishida, Yousef Salama, Ismael Gritli, Terumasa Umemoto, Hiromitsu Nakauchi, Koichi Hattori, Heissig Beate
Journal: Blood (2014)
The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells
Authors: Y Nishida, A Maeda, M J Kim, L Cao, Y Kubota, J Ishizawa, A AlRawi, Y Kato, A Iwama, M Fujisawa, K Matsue, M Weetall, M Dumble, M Andreeff, T W Davis, A Branstrom, S Kimura, K Kojima
Journal: Blood Cancer Journal (2017)

Disease recurrence is the major problem in the treatment of acute myeloid leukemia (AML). Relapse is driven by leukemia stem cells, a chemoresistant subpopulation capable of re-establishing disease. Patients with p53 mutant AML are at an extremely high risk of relapse. B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) is required for the self-renewal and maintenance of AML stem cells. Here we studied the effects of a novel small molecule inhibitor of BMI-1, PTC596, in AML cells. Treatment with PTC596 reduced MCL-1 expression and triggered several molecular events consistent with induction of mitochondrial apoptosis: loss of mitochondrial membrane potential, BAX conformational change, caspase-3 cleavage and phosphatidylserine externalization. PTC596 induced apoptosis in a p53-independent manner. PTC596 induced apoptosis along with the reduction of MCL-1 and phosphorylated AKT in patient-derived CD34+CD38low/- stem/progenitor cells. Mouse xenograft models demonstrated in vivo anti-leukemia activity of PTC596, which inhibited leukemia cell growth in vivo while sparing normal hematopoietic cells. Our results indicate that PTC596 deserves further evaluation in clinical trials for refractory or relapsed AML patients, especially for those with unfavorable complex karyotype or therapy-related AML that are frequently associated with p53 mutations.
Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta® in the prophylaxis of chemotherapy-induced neutropenia
Authors: C.F. Waller, C. Blakeley, E. Pennella, M. Bronchud, O. Berzoy, N. Voitko, H. Adamchuk, Z. Zautashvili, Y. Vinnyk, G. Nemsadze, G. Dzagnidze, Y. Shparyk, I. Lytvyn, A. Rusyn, V. Popov, I. Lang, R. Sharma, M. Baczkowski, M. Kothekar, A. Barve
Journal: Annals of Oncology (2016)
90Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial
Authors: Kristina Lerch, Corinna Leng, Antonello Pinto, Werner Linkesch, Heinz Sill, Ola Linden, Andreas Viardot, Ulrich Keller, Georg Hess, Secondo Lastoria, Ferdinando Frigeri, Nicole Neik, Christiane Pott, Christian W. Scholz, Antonio Pezzutto
Journal: Blood (2016)
Comprehensive Genomic Copy Number and Sequence Analysis of 28 Chromosome 5q31.2 Candidate Genes in De Novo MDS.
Authors: Timothy A. Graubert, M.A. Payton, R.S. Monahan, J. Shao, J.L. Frater, R.A. Walgren, Y. Kasai, Matthew J. Walter
Journal: Blood (2007)
Modified BEP chemotherapy in patients with testicular germ-cell tumors treated at a Comprehensive Cancer Center
Authors: E. Verri, G. Aurilio, M. Cossu Rocca, D. Radice, D. Cullurà, O. De Cobelli, G. Musi, B. Jereczec, R. Iacovelli, G. Curigliano, F. Nolè
Journal: Annals of Oncology (2016)
Cross-cultural adaptation of the US National Cancer Institute's PRO-CTCAE instrument into Italian for adult cancer patients
Authors: S. Riva, C. Caminiti, E. Iannelli, J. Bryce, M. Bagnalasta, F. Arpinelli, M. Bassi, P. Betteto, L. Del Mastro, D. De Persis, A.L. Nicelli, R. Passalacqua, C. Porta, L. Sparavigna, F. Diodati, C. Piparo, S. Novello, K. Castro, S.A. Mitchell, F. Perrone
Journal: Annals of Oncology (2016)
Impact of Early Blast Clearance Following Induction Chemotherapy On the Outcome of Patients with Acute Myelod Leukemia Undergoing Allogeneic Stem Cell Transplantation in First Complete Remission
Authors: Philipp G. Hemmati, Theis H. Terwey, Philipp le Coutre, Gero Massenkeil, Bernd Dörken, Renate Arnold
Journal: Blood (2012)
Head accelerations across collegiate, high school and youth female and male soccer players
Authors: Jaclyn B Caccese
Journal: British Journal of Sports Medicine (2017)

I investigated (1) head acceleration during purposeful football heading across age and sex and (2) determinants of head impact severity.

Nearly 4% of the world’s population plays football, including over 26 million women. Although there are unrefuted positive health effects of playing football,1 chronic traumatic encephalopathy (CTE) has been identified in three football players,2 including British player, Jeffrey Astle, causing concern about the long-term effects of repetitive heading. To prevent or mitigate the effects of repetitive football heading, I believe that we must understand the biomechanics and identify strategies for reducing head impact severity.3 Currently, the little information on the biomechanical response to purposeful heading is limited to collegiate male football players, but these data may not be transferable to women and children, who have lower head mass, decreased neck muscle …
Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia
Authors: Steven P Treon, Nicholas Tsakmaklis, Kirsten Meid, Guang Yang, Jiaji G Chen, Xia Liu, Jie Chen, Maria Demos, Christopher J Patterson, Toni Dubeau, Joshua Gustine, Jorge J. Castillo, Ranjana H Advani, Maria Lia Palomba, Lian Xu, Zachary Hunter
Journal: Blood (2016)
Effect of Lower Hematocrits on Buffy Coat Collection during Extracorporeal Photopheresis in Patients with Graft-Versus-Host Disease
Authors: Emily Schindler, Michael LeRoy, Katherine Martin-bredahl, Michaela Dino, Kalpna Shah, Marian Dynis, Charles S. Eby, Chang Liu, Brenda J. Grossman
Journal: Blood (2015)
Compliance with oral cancer medications when dispensed in the oncology clinic vs. when provided directly by healthcare payers: a prospective multicenter study by the Oncoclinicas Group
Authors: F.F. Gomes, E.M. Sobrinho, R. Miranda, L. Mercurio, M. Dias, K. Nascimento, A. Alves, E. Tavares, L. Teixeira, O. Silva, P. Fernandes, F. Reis, T. Rios, C. Silva, G. Lopes
Journal: Annals of Oncology (2016)
ATIM-27. PHASE I INVESTIGATION OF LENALIDOMIDE PLUS RITUXIMAB AND OUTCOMES OF LENALIDOMIDE MAINTENANCE IN RECURRENT CNS LYMPHOMA
Authors: James Rubenstein, Eleanor Fraser, Paul Formaker, James Chi-Chiang Lee, Nianhang Chen, Mallory Kock, Wesley Cheung, Phoebe Killea, Kee-Hyun Choi, Xiaomin Wang, Pamela Munster, Bertil Damato
Journal: Neuro-Oncology (2016)

There is an unmet need for effective biological therapies for relapsed CNS lymphoma. We demonstrated activity of the immunomodulatory agent lenalidomide (CC-5013) in preclinical models of refractory CNS DLBCL. These observations are the basis for this first trial of IMiD monotherapy in CNS NHL, and in patients with inadequate responses to lenalidomide, with intravenous plus intraventricular rituximab. In an independent cohort we evaluated lenalidomide maintenance in relapsed CD20+ CNS NHL. Primary objective was to evaluate safety and efficacy of lenalidomide at 3 dose levels. Secondary endpoints were to determine: CSF penetration of lenalidomide; feasibility of intraventricular plus intravenous rituximab; TTP of maintenance lenalidomide in an independent cohort of relapsed patients. Fourteen subjects with refractory CNS DLBCL (median age 66) were treated on the phase I protocol. 9 achieved > PR with lenalidomide: 3 CR’s, 1 PR in brain parenchymal NHL; 2 CR of CSF NHL; 1 CR, 3 PR’s of intraocular NHL. Four maintained CR to lenalidomide > 9 months and two > 1.8 years. An independent cohort of 14 patients with recurrent CNS DLBCL (median age 65) received lenalidomide as maintenance after salvage. With median follow-up of > 18 months, TTP has been impressive: five maintained remissions > 2 years. Among 12 CNS DLBCL patients with multiple CNS relapses that received focal XRT or HD-MTX-rituximab salvage, followed by lenalidomide maintenance, TTP at CR 2-4 was >5 X longer than TTP in these patients after standard induction and consolidation chemotherapy, without lenalidomide. P<0.013; Hazard Ratio 3.75. Trough lenalidomide concentration in ventricular CSF was highest at 20 mg dose. Elevated CSF lactate predicted short PFS (p<0.01). Lenalidomide penetrates ventricular CSF and is active in relapsed CNS DLBCL. We provide the first evidence that maintenance lenalidomide significantly potentiates TTP after salvage in relapsed CNS DLBCL and delays WBRT.
Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases
Authors: Yan-Li Zhao, Tong Wu, Yue Lu, Xing-Yu Cao, De-Yan Liu, Min Xiong, Jian-Ping Zhang, Zhi-Jie Wei, Jia-Rui Zhou, Rui-Juan Sun, Chun-Rong Tong, Hong-Xing Liu, Hui Wang, Tong Wang, Shu-Quan Ji, Dao-Pei Lu
Journal: Blood (2015)
Various Germline Congenital Disorder Genes Are Somatically Mutated in Myeloid Malignancies
Authors: Naoko Hosono, Hasan Rehman, Bartlomiej Przychodzen, Ines Gomez-Segui, Kathryn M Guinta, Kenichi Yoshida, Satoru Miyano, Yuichi Shiraishi, Seishi Ogawa, Jaroslaw P. Maciejewski, Hideki Makishima
Journal: Blood (2012)
Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions
Authors: Amelie V. Guitart, Theano I. Panagopoulou, Arnaud Villacreces, Milica Vukovic, Catarina Sepulveda, Lewis Allen, Roderick N. Carter, Louie N. van de Lagemaat, Marcos Morgan, Peter Giles, Zuzanna Sas, Marta Vila Gonzalez, Hannah Lawson, Jasmin Paris, Joy Edwards-Hicks, Katrin Schaak, Chithra Subramani, Deniz Gezer, Alejandro Armesilla-Diaz, Jimi Wills, Aaron Easterbrook, David Coman, Chi Wai Eric So, Donal O’Carroll, Douglas Vernimmen, Neil P. Rodrigues, Patrick J. Pollard, Nicholas M. Morton, Andrew Finch, Kamil R. Kranc
Journal: The Journal of Experimental Medicine (2017)

Strict regulation of stem cell metabolism is essential for tissue functions and tumor suppression. In this study, we investigated the role of fumarate hydratase (Fh1), a key component of the mitochondrial tricarboxylic acid (TCA) cycle and cytosolic fumarate metabolism, in normal and leukemic hematopoiesis. Hematopoiesis-specific Fh1 deletion (resulting in endogenous fumarate accumulation and a genetic TCA cycle block reflected by decreased maximal mitochondrial respiration) caused lethal fetal liver hematopoietic defects and hematopoietic stem cell (HSC) failure. Reexpression of extramitochondrial Fh1 (which normalized fumarate levels but not maximal mitochondrial respiration) rescued these phenotypes, indicating the causal role of cellular fumarate accumulation. However, HSCs lacking mitochondrial Fh1 (which had normal fumarate levels but defective maximal mitochondrial respiration) failed to self-renew and displayed lymphoid differentiation defects. In contrast, leukemia-initiating cells lacking mitochondrial Fh1 efficiently propagated Meis1/Hoxa9-driven leukemia. Thus, we identify novel roles for fumarate metabolism in HSC maintenance and hematopoietic differentiation and reveal a differential requirement for mitochondrial Fh1 in normal hematopoiesis and leukemia propagation.